Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Am J Cardiol. 2024 Sep 15;227:18-28. doi: 10.1016/j.amjcard.2024.07.017. Epub 2024 Jul 18.
Chronic total occlusions (CTO) of the coronary arteries are common among patients presenting to the cardiac catheterization laboratory, and data suggests a worse overall prognosis in patients with CTOs. Percutaneous coronary intervention (PCI) of CTOs has been shown to improve anginal symptoms in observational studies and in a limited number of randomized trials. However, CTO PCI has not been shown to lead to a reduction in other important end points such as myocardial infarction or death. Furthermore, despite recent advances in the field, CTO PCI still carries higher risks and a lower likelihood of success compared with non-CTO PCI. Thus, determining which patients may be appropriate for CTO PCI is challenging and must involve a comprehensive risk-benefit analysis and discussion with the patient. Therefore, we review the currently available data regarding CTO PCI, including the clinical outcomes, the role of preprocedural ischemia testing, and various procedural success and risk stratification scores. Finally, we present our approach to the patient referred for CTO PCI.
冠状动脉慢性完全闭塞(CTO)在就诊于心脏导管实验室的患者中很常见,数据表明 CTO 患者的整体预后更差。观察性研究和少数随机试验表明,经皮冠状动脉介入治疗(PCI)可改善 CTO 患者的心绞痛症状。然而,CTO PCI 并未显示可降低其他重要终点事件(如心肌梗死或死亡)的发生。此外,尽管该领域最近取得了进展,但与非 CTO PCI 相比,CTO PCI 仍然具有更高的风险和更低的成功率。因此,确定哪些患者可能适合进行 CTO PCI 具有挑战性,必须进行全面的风险效益分析,并与患者进行讨论。因此,我们回顾了目前关于 CTO PCI 的可用数据,包括临床结果、术前缺血检测的作用以及各种手术成功率和风险分层评分。最后,我们介绍了我们对接受 CTO PCI 治疗的患者的处理方法。